Skip to main content
Year archive

BioArctic — 2019 filings

All 40 regulatory filings released by BioArctic (BIOA) in 2019, sourced directly from the official regulator.

40 Filings
2019 Period
2019 filings (40)
Filing Released Lang
BioArctic announces research collaboration with Eisai regarding BAN2401
Regulatory Filings
2019-12-17 English
BioArctic tillkännager utökat forskningssamarbete med Eisai kring BAN2401
Regulatory Filings
2019-12-17 Swedish
BioArctic’s partner Eisai presents data from the ongoing BAN2401 Phase 2b extension study in early Alzheimer’s disease
Regulatory Filings
2019-12-09 English
BioArctics partner Eisai presenterar data från den pågående förlängningsstudien efter Fas 2b med BAN2401 i tidig Alzheimers sjukdom
Investor Presentation
2019-12-09 Swedish
BioArctic announces results from interim analysis of the Phase 1/2 study of SC0806 in patients with complete spinal cord injury
Legal Proceedings Report
2019-11-18 English
BioArctic meddelar interimsresultat från Fas 1/2-studien med SC0806 för behandling av patienter med komplett ryggmärgsskada
Regulatory Filings
2019-11-18 Swedish
BioArctic presenterar valberedningen och offentliggör finansiell kalender
AGM Information
2019-11-05 Swedish
BioArctic presents Nomination Committee and publishes financial calendar 2020
AGM Information
2019-11-05 English
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-10-24 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-10-24 English
Interim / Quarterly Report 2019
Interim / Quarterly Report H2 2019
2019-07-11 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H2 2019
2019-07-11 English
BioArctic strengthens its blood-brain barrier technology platform with world leading scientist recruitment
Board/Management Information
2019-05-23 English
BioArctic förstärker sin blod-hjärnbarriär teknikplattform med en expertrekrytering
Board/Management Information
2019-05-23 Swedish
BioArctic erhåller milstolpsersättning om 15 MEUR från Eisai då den bekräftande Fas 3-studien med BAN2401 i tidig Alzheimers sjukdom startat
Regulatory Filings
2019-05-20 Swedish
BioArctic receives MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s Disease
Regulatory Filings
2019-05-20 English
BioArctic - kommuniké från årsstämma 2019
AGM Information
2019-05-09 Swedish
BioArctic – report from the Annual General Meeting 2019
AGM Information
2019-05-09 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-09 Swedish
Earnings Release 2019
Earnings Release Q1 2019
2019-05-09 English
Annual Report 2018
Annual Report FY 2018
2019-04-16 English
Annual Report 2018
Annual Report FY 2018
2019-04-16 Swedish
KALLELSE TILL ÅRSSTÄMMA I BIOARCTIC AB (PUBL)
AGM Information
2019-04-10 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)
AGM Information
2019-04-10 English
BioArctics partner Eisai initierar den bekräftande Fas 3-studien av BAN2401 för tidig Alzheimers sjukdom
Regulatory Filings
2019-03-22 Swedish
BioArctic’s partner Eisai initiates the confirmatory Phase 3 study of BAN2401 in early Alzheimer’s Disease
Regulatory Filings
2019-03-22 English
BioArctic – Statement regarding today’s trading halt
Earnings Release FY 2019
2019-03-21 English
BioArctic - Kommentar med anledning av handelsstopp
Regulatory Filings
2019-03-21 Swedish
BioArctic meddelar start av klinisk Fas 1-studie med ABBV-0805 för Parkinsons sjukdom
Regulatory Filings
2019-03-13 Swedish
BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease
Regulatory Filings
2019-03-13 English
BioArctic: Eisai announces timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer’s disease
Investor Presentation
2019-03-07 English
BioArctic: Eisai informerar om tidplanen för den enda bekräftande Fas 3-studien med BAN2401 för tidig Alzheimers sjukdom
Regulatory Filings
2019-03-07 Swedish
Earnings Release 2018
Earnings Release FY 2018
2019-02-14 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report FY 2018
2019-02-14 English
BioArctics produktkandidat SC0806 för behandling av patienter med komplett ryggmärgsskada är nu i Fas 2
Regulatory Filings
2019-02-13 Swedish
BioArctic’s product candidate SC0806 for treatment of patients with complete spinal cord injury is now in Phase 2
Legal Proceedings Report
2019-02-13 English
BioArctic: Amerikanska läkemedelsmyndigheten, FDA, godkänner Investigational New Drug-ansökan för ABBV-0805
Regulatory Filings
2019-02-11 Swedish
BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805
Regulatory Filings
2019-02-11 English
BioArctic announces that Eisai will initiate Phase 3 confirmatory study with BAN2401 in early Alzheimer’s Disease
Regulatory Filings
2019-02-04 English
BioArctic meddelar att Eisai kommer att starta en bekräftande Fas 3-studie med BAN2401 för tidig Alzheimers sjukdom
Regulatory Filings
2019-02-04 Swedish